iiinova — where your digital self keeps evolving

Reposted by Marshall Strother

NEJM.org @nejm.org · 01/06/2025

Late breaking at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial: nej.md/4mh5RPL @ascocancer.bsky.social

25027

Reposted by Marshall Strother

NEJM.org @nejm.org · 29/03/2025

In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full results: nej.md/41YkRZK #ACC25 | @accintouch.bsky.social

A graph showing the cumulative incidence of recurrent venous thromboembolism (primary efficacy outcome) among patients who received apixaban at a reduced (2.5 mg) or full (5.0 mg) dose twice daily for 12 months.

1188

Reposted by Marshall Strother

NEJM.org @nejm.org · 22/03/2025

In patients with bloodstream infection, early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. Research findings on treatment duration in hospitalized patients are summarized in a new Quick Take video. youtu.be/V68RQ6XwiKQ #MedSky #PulmSky #IDSky

A visual representation of the uncertain treatment duration for patients with bloodstream infection

0173

Reposted by Marshall Strother

Sophie Greenwood @sjgreenwood.bsky.social · 10/03/2025

Please repost to get the word out! @nkgarg.bsky.social and I are excited to present a personalized feed for academics! It shows posts about papers from accounts you’re following bsky.app/profile/pape...

8171118

Marshall Strother @mcstroth.bsky.social · 13/03/2025

Looked for sure like hematuria to me... I will truly never run out of new stuff to learn about pee apparently

020

Reposted by Marshall Strother

BJUI & BJUI Compass @bjuijournal.bsky.social · 13/03/2025

Just published: Robotic ileal ureter replacement vs kidney autotransplantation for long ureteric strictures bjui.pub/41G1zrH

Abstract
Objective
To compare functional and surgical outcomes of robot-assisted ileal ureter replacement (RAIUR) vs robot-assisted kidney autotransplantation (RAKAT).
Patients and Methods

This was a retrospective analysis of patients who underwent RAIUR or RAKAT for long ureteric strictures at eight European tertiary centres (2017–2024). Primary endpoints were maintenance of estimated glomerular filtration rate (eGFR) and postoperative complications within 30 days of surgery, described using the Clavien–Dindo classification. Secondary outcomes included infections, need for lifelong drainage, stricture persistence, and re-intervention for the stricture during follow-up.
Results

A total of 15 and 39 patients underwent RAIUR and RAKAT, respectively. The patients who underwent RAIUR were older (61 vs 45 years, P = 0.03), with more comorbidities (Charlson Comorbidity Index ≥3: 67% vs 28%, P = 0.03) and had a lower baseline eGFR (60 vs 87 mL/min/1.73m2, P = 0.007). The median stricture length was 9.6 cm for RAIUR vs 7 cm for RAKAT. Patients who underwent RAIUR had a shorter surgical time (290 vs 355 min, P = 0.008), whereas those who underwent RAKAT had a shorter hospitalisation (5 vs 8 days, P = 0.001). Overall complications were higher after RAIUR (73% vs 31%, P = 0.01), but Clavien–Dindo Grade ≥III complications were similar (13% vs 10%). During follow-up, both groups showed slightly improved renal function, low infection rates (13% for RAIUR vs 10% for RAKAT), low stricture persistence (13% for RAIUR vs 7.7% for RAKAT), and minimal need for drainage or re-intervention. The main limitation was the modest sample size.

021

Reposted by Marshall Strother

Elizabeth Plimack MD @erplimackmd.bsky.social · 15/02/2025

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

083

Marshall Strother @mcstroth.bsky.social · 29/01/2025

My favorite SHIM score is 1,5,5,5,5, which is a man with good erections who interpreted the first question ("How do you rate your confidence that you could get and keep an erection?") to mean RIGHT NOW on command here in my office. It's a very poorly worded question.

010

Reposted by Marshall Strother

Adam Grant @adamgrant.bsky.social · 26/01/2025

The clearest sign of intellectual chemistry isn’t agreeing with someone. It’s enjoying your disagreements with them. Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments. Creative tension makes beautiful music.

481775233

Reposted by Marshall Strother

Matt Cooperberg @dr-coops.bsky.social · 16/01/2025

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10....

2104

Reposted by Marshall Strother

NEJM.org @nejm.org · 15/01/2025

A man with prostate cancer who was receiving androgen blockade had a substantial reduction in the frequency of hot flashes with the use of fezolinetant. Read the full correspondence: nej.md/3DNhtbx #MedSky

nej.md

Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men | NEJM

A man with prostate cancer who was receiving androgen blockade had a substantial reduction in the frequency of hot flashes with the use of fezolinetant.

0102

Reposted by Marshall Strother

Todd Morgan, MD @wandering-gu.bsky.social · 05/12/2024

Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24

1184